5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Selective killing of lung cancer cells by miRNA-506 molecule through inhibiting NF-κB p65 to evoke reactive oxygen species generation and p53 activation.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The tumor suppressor p53, nuclear factor-κB (NF-κB) and reactive oxygen species (ROS) have crucial roles in tumorigenesis, although the mechanisms of cross talk between these factors remain largely unknown. Here we report that miR-506 upregulation occurs in 83% of lung cancer patients (156 cases), and its expression highly correlates with ROS. Ectopic expression of miR-506 inhibits NF-κB p65 expression, induces ROS accumulation and then activates p53 to suppress lung cancer cell viability, but not in normal cells. Interestingly, p53 promotes miR-506 expression level, indicating that miR-506 mediates cross talk between p53, NF-κB p65 and ROS. Furthermore, we demonstrated that miR-506 mimics inhibited tumorigenesis in vivo, implicating that miR-506 might be a potential therapeutic molecule for selective killing of lung cancer cells.

          Related collections

          Author and article information

          Journal
          Oncogene
          Oncogene
          1476-5594
          0950-9232
          Feb 5 2015
          : 34
          : 6
          Affiliations
          [1 ] 1] The State Key Laboratory of Respiratory Diseases, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China [2] School of Life Science, University of Science and Technology of China, Hefei, China.
          [2 ] Department of Cardiothoracic Surgery, The First Affiliated Hospital of Guangzhou Medical College, Guangzhou, China.
          [3 ] Guangzhou RiboBio Co., Ltd, Guangzhou, China.
          [4 ] The State Key Laboratory of Respiratory Diseases, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
          [5 ] University of Chinese Academy of Sciences, Beijing, China.
          [6 ] School of Life Science, University of Science and Technology of China, Hefei, China.
          [7 ] 1] The State Key Laboratory of Respiratory Diseases, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China [2] University of Chinese Academy of Sciences, Beijing, China.
          Article
          onc2013597
          10.1038/onc.2013.597
          24469051
          6222e2eb-13ac-4ffd-8d97-80aadf100ce5
          History

          Comments

          Comment on this article